EnVivo Pharmaceuticals, Inc. Initiates COGNITIV AD, A Phase 3 Clinical Trial Program Of Encenicline (EVP-6124) In Alzheimer’s Disease

Published: Jan 22, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system (CNS) diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (a7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer’s disease (AD). The program is being conducted under a Special Protocol Assessment agreement with the FDA.

Help employers find you! Check out all the jobs and post your resume.

Back to news